Sandoz Group AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: HX575 epoetin alfa (Sandoz)
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 417
- Registration Number
- NCT01576341
- Locations
- 🇺🇦
Sandoz Investigative Site, Zhitomyr, Ukraine
Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim
- Conditions
- Chemotherapy Associated NeutropeniaBreast Cancer
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 218
- Registration Number
- NCT01519700
- Locations
- 🇭🇺
Semmelweis Egyetem, III. Belgyogyaszati Klinika, Budapest, Hungary
🇷🇺Institution of the Russian Academy of Medical Sciences Medical Radiology Research Center RAMS, Obninsk, Russian Federation
🇷🇺State Healthcare Institution (SHI)"Voronezh Regional Clinical Oncological Dispensary", Voronezh, Russian Federation
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
- Conditions
- Breast CancerChemotherapy-induced Neutropenia
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 308
- Registration Number
- NCT01516736
- Locations
- 🇪🇸
Sandoz Investigational Site, Valencia, Spain
Long-term Safety Follow-up After Growth Hormone Treatment of Short Children Born Small for Gestational Age
- Conditions
- Short Children Born Small for Gestational Age (SGA)
- Interventions
- Other: Bloodsampling
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 130
- Registration Number
- NCT01491854
- Locations
- 🇷🇴
Novartis Investigative Site, Cluj Napoca, Romania
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
- Conditions
- Ovarian CancerFebrile NeutropeniaCancerProstate CancerLung CancerBladder CancerB-cell LymphomaBreast CancerMultiple Myeloma
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 1496
- Registration Number
- NCT01459653
- Locations
- 🇬🇧
Sandoz Investigational Site, Scunthorpe, United Kingdom
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)
- Conditions
- Follicular Lymphoma
- Interventions
- Biological: rituximabBiological: GP2013
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 629
- Registration Number
- NCT01419665
- Locations
- 🇮🇳
Investigtive site, Kolkata, India
🇧🇷Investigative Site, Rio de Janeiro, Brazil
🇮🇳India, Amritsar, India
Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft Rejection
- Conditions
- Chronic Kidney Insufficiency
- Interventions
- Other: In this observational study no study specific intervention is planned
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 102
- Registration Number
- NCT01353417
- Locations
- 🇦🇹
General Hospital, Vienna, Austria
A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 727
- Registration Number
- NCT01279057
- Locations
- 🇺🇸
Sandoz Investigational Site, Waco, Texas, United States
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: MabTheraBiological: GP2013Biological: Rituxan
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 312
- Registration Number
- NCT01274182
- Locations
- 🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸Physician Research Collaboration, LLC, Lincoln, Nebraska, United States
🇺🇸Bluegrass Community Research, Inc., Lexington, Kentucky, United States
Clinical Trial With Mesalamine 1g Suppositories
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 158
- Registration Number
- NCT01172444
- Locations
- 🇮🇳
Dr. Nijhawan's Clinic, Jaipur, Rajasthan, India
🇮🇳Kala Endoscopy & Liver Clinic, Jodhpur, Rajasthan, India
🇮🇳Sharma Gastroenterology Centre, Jaipur, Rajasthan, India